AKTSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Aktis Oncology, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$15.11+0.05 (+0.33%)
Close on Oct 19, 2026
- Market cap
- $835.58M
- P/E (TTM)
- –
- Dividend yield
- –
Aktis Oncology, Inc. cash flow statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- –
Financial strength
- Current ratio
- 16.33
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 256.8%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.72
- Dividend yield
- –